Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Fatal Myositis Due to the Microsporidian Brachiola algerae, a Mosquito Pathogen
NEJM 351:42-47, Coyle,C.M.,et al, 2004
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria
NEJM 377:2581-2590, Case 40-2017, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
Fatal Varicella-Zoster Virus Vasculopathy Associated with Adalimumab Therapy
Arch Neurol 69:1193-1196, Baek, W.,et al, 2012
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Clinicopath Conf,Sarcoidosis,with Involvement of Spinal Cord,Brain,Mediastinal Lymph Nodes and ? Lung,Case 35-1998
NEJM 339:1534-1541, , 1998
Neurotoxicity After Treatment with Muromonab-CD3
NEJM 323:487-488, Richards,J.M.,et al, 1990
OKT3 Encephalopathy
Ann Neurol 28:837-838, Coleman,A.E.&Norman,D.J., 1990
Serum Antibodies to GM1 Ganglioside in Amytrophic Lateral Sclerosis
Neurol 38:1457-1461, Pestronk,A.,et al, 1988